Abstract
We examined the degradation of Alzheimer's ß-amyloid protein (1–40) by soluble and synaptic membrane fractions from post mortem human and fresh rat brain using HPLC. Most of the activity at neutral pH was in the soluble fraction. The activity was thiol and metal dependent, with a similar inhibition profile to insulin-degrading enzyme. Immunoprecipitation of insulin-degrading enzyme from the human soluble fraction using a monoclonal antibody removed over 85% of the ß-amyloid protein degrading activity. Thus insulin-degrading enzyme is the main soluble ß-amyloid degrading enzyme at neutral pH in human brain. The highest ß-amyloid protein degrading activity in the soluble fractions occurred between pH 4–5, and this activity was inhibited by pepstatin, implicating an aspartyl protease. Synaptic membranes had much lower ß-amyloid protein degrading activity than the soluble fraction. EDTA (2mM) caused over 85% inhibition of the degrading activity but inhibitors of endopeptidases −24.11, −24.15, −24.16, angiotensin converting enzyme, aminopeptidases, and carboxypeptidases had little or no effect.
Similar content being viewed by others
REFERENCES
Glenner, G. G., and Wong, C. W. 1984. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 112:1131–1135.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82:4245–4249.
Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell surface receptor. Nature 325:733–736.
Goldgaber, D., Leman, M. I., McBride, O. W., Saffiotti, U., and Gadjusek, D. C. 1987. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 235:877–880.
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., and Younkin, S. G. 1992. Production of the Alzheimer amyloid β-protein by normal proteolytic processing. Science 258:126–129.
Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B., and Selkoe, D. J. 1993. β-amyloid peptide and a 3-kDa fragment are derived by distinct molecular mechanisms. J. Biol. Chem. 268:3021–3024.
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., and Schenk, D. 1992. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 359:325–327.
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., and Selkoe, D. J. 1992. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359:322–325.
Esch, F. S., Keim, P. S., Beattie, E. C., Blacker, R. W., Culwell, A. K., Oltersdorf, T., McClure, D., and Ward, P. J. 1990. Cleavage of amyloid β-peptide during constitutive processing of its precursor. Science 248:1122–1124.
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D. J. 1992. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360:672–674.
Cai, X., Golde, T. E., and Younkin, S. G. 1993. Release of excess amyloid-β protein from a mutant amyloid-β protein precursor. Science 259:514–516.
Duckworth, W. C. 1988. Insulin degradation: mechanisms, products and significance. Endocrin. Rev. 9:319–345.
Kurochkin, I. V., and Goto, S. 1994. Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345:33–37.
McDermott, J. R., and Gibson, A. M. 1995. Identification and characterization of central nervous system peptidase activities. Pages 281–295, in Smith A. I., (ed), Methods in Neurosciences, Vol 23: Peptidases and neuropeptide processing pp. 281–295. Academic Press, San Diego.
Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248–254.
Duckworth, W. C., Heinemann, M., and Kitabchi, A. E. 1972. Purification of insulin specific protease by affinity chromatography. Proc. Natl. Acad. Sci. USA 69:3698–3702.
Jarrett, J. T., Berger, E. P., and Lansburg, P. T. 1993. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693–4697.
Authier, F., Rachubinski, R. A., Posner, B. I., and Bergeron, J. J. M. 1994. Endosomal proteolysis of insulin by an acidic thiol metalloprotease unrelated to insulin degrading enzyme. J. Biol. Chem. 269:3010–3016.
Hardy, J., and Allsop, D. 1991. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12:383–388.
Selkoe, D. J. 1994. Normal and abnormal biology of the β-amyloid precursor protein. Ann. Rev. Neurosci. 17:489–517.
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., and Lannfelt, L. 1992. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nature Genet. 1:345–347.
Axelman, K., Basun, H., Winblad, B., and Lannfelt, L. 1994. A large Swedish family with Alzheimer's disease with a codon 670/671 amyloid precursor protein mutation. Arch. Neurol. 51:1193–1197.
Howell, S., Nalbantoglu, J., and Crine, P. 1995. Neutral endopeptidase can hydrolyze β-amyloid(1–40) but shows no effect on β-amyloid precursor protein metabolism. Peptides 16:647–652.
Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J., and Fridman, R. 1994. Proteolysis of Aß peptide from Alzheimer disease brain by gelatinase A. Biochem. Biophys. Res. Commun. 205:1755–1761.
Marks, N., Berg, M. J., Chi, L. M., Choi, J., Durrie, R., Swistok, J., Makofske, R. C., Danho, W., and Sapirstein, V. S. 1994. Hydrolysis of amyloid precursor protein-derived peptides by cysteine proteinases and extracts of rat brain clathrin-coated vesicles. Peptides 15:175–182.
Norstedt, C., Näslund, J., Tjernberg, L. O., Karlström, A. R., Thyberg, J., and Terenius, L. 1994. The Alzheimer Aß peptide develops protease resistance in association with its polymerization into fibrils. J. Biol. Chem. 269:30773–30776.
Bush, A. L., Pettingell, W. H., Paradis, M., and Tanzi, R. E. 1994. Modulation of Aß adhesiveness and secretase site cleavage by zinc. J. Biol. Chem. 269:12152–12158.
McDermott, J. R., and Gibson, A. M. 1991. The processing of Alzheimer A4/ß-amyloid protein precursor: identification of a human brain metallopeptidase which cleaves-Lys-Leu-in a model peptide. Biochem. Biophys. Res. Commun. 179:1148–1154.
Tagawa, K., Kunishita, T., Maruyama, K., Yoshikawa, K., Kominami, E., Tsuchiya, T., Suzuki, K., Tabira, T., Sugita, H., and Ishiura, S. 1991. Alzheimer's disease amyloid β-clipping enzyme (APP secretase): identification, purification and characterization of the enzyme. Biochem. Biophys. Res. Commun. 177:377–387.
Skidgel, R. A., Engelbrecht, S., Johnson, A. R., and Erdös, E. G. 1984. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5:769–776.
Kenny, A. J., Bowes, M. A., Gees, N. S., and Matsas, R. 1985. Endopeptidase 24.11: a cell surface enzyme for metabolizing regulatory peptides. Biochem. Soc. Trans. 13:293–295.
Barelli, H., Vincent, J.-P., and Checler, F. 1993. Rat kidney endopeptidase 24.16. Eur. J. Biochem. 211:79–80.
Allholter, J. A., Hsieh, C.-L., Francke, U., and Roth, R. A. 1990. Insulin-degrading enzyme: stable expression of the human complementary DNA, characterization of its protein product, and chromosomal mapping of the human and mouse genes. Mol. Endocrinol. 4:1125–1135.
Baumeister, H., Müller, D., Rehbein, M., and Richter, D. 1993. The rat insulin-degrading enzyme: molecular cloning and characterization of tissue-specific transcripts. FEBS Lett. 317:250–254.
Kuo, W.-L., Gehm, B. D., Rosner, M. R., Li, W., and Keller, G. 1994. Inducible expression and cellular localization of insulin-degrading enzyme in a stably transfected cell line. J. Biol. Chem. 269:22599–22606.
Kuo, W.-L., Gehm, B. D., and Rosner, M. R. 1991. Regulation of insulin degradation: expression of an evolutionary conserved insulin-degrading enzyme increases degradation via an intracellular pathway. Mol. Endocrinol. 5:1467–1476.
Yokono, K., Roth, R. A., and Baba, S. 1982. Identification of insulin degrading enzyme on the surface of cultured human lymphocytes, rat hepatoma cells and primary cultures of rat hepatocytes. Endocrinology 111:1102–1108.
Fleig, W. E., Hoss, G., Nother-Fleig, B., and Ditschuneit, H. 1986. Insulin binding to cultured adult hepatocytes: effects of bacitracin and chloroquine on the nature of cell associated radioactivity. Biochem. J. 237:99–104.
Caro, J. F., Muller, G., and Gennon, J. A. 1982. Insulin processing by liver. J. Biol. Chem. 257:8459–8466.
Hamel, F. G., Posner, B. I., Bergeron, J. J. M., Frank, B. H., and Duckworth, W. C. 1988. Isolation of insulin degradation products from endosomes derived from intact rat liver. J. Biol. Chem. 263:6703–6708.
McDermott, J. R., and Gibson, A. M. 1996. Degradation of Alzheimer's β-amyloid protein by human cathepsin D. NeuroReport, 7: (in press).
Cataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., Lippa, C., and Nixon, R. A. 1995. Gene expression and cellular content of cathepsin D in human neocortex: evidence for early upregulation of the endosomal-lysosomal system in pyramidal neurons in Alzheimer disease. Neuron 14:1–20.
Cataldo, A. M., Paskevich, P. A., Kominami, E., and Nixon, R. A. 1991. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA. 88:10998–11002.
Schwagerl, A. L., Mohan, P. S., Cataldo, A. M., Vonsattel, J. P., Kowall, N. W., and Nixon, R. A. 1995. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J. Neurochem. 64:443–446.
Mantle, D., Falkous, G., Ishiura, S., Perry, R. H., and Perry, E. K. 1995. Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. J. Neurol. Sci. 131:65–70.
Turner, A. J., Hooper, N. M., and Kenny, A. J. 1987. Metabolism of neuropeptides. Pages 211–248, in Kenny, A. J. and Turner, A. J., (eds), Mammalian Ectoenzymes. Elsevier, Amsterdam.
Checler, F. 1993. Neuropeptide degrading peptidases. Pages 375–417, in Parvez, S. H., Naoi, M., Nagatsu, T., and Parvez, S. (eds), Methods in Neurotransmitters and Neuropeptide Research, Elsevier, Amsterdam.
Perera, I. K., Candy, J. M., Håkansson, P., Oakley, A. E., Brinkmalm, G., and Sundqvist, B. U. R. 1990. UV-laser-induced desorption mass spectrometry of insulin, substance P and A4 amyloid protein fragments from synthetic fibrillary aggregates. Rapid Commun. in Mass Spectrom. 4:527–532.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McDermott, J.R., Gibson, A.M. Degradation of Alzheimer's ß-Amyloid Protein by Human and Rat Brain Peptidases: Involvement of Insulin-Degrading Enzyme. Neurochem Res 22, 49–56 (1997). https://doi.org/10.1023/A:1027325304203
Issue Date:
DOI: https://doi.org/10.1023/A:1027325304203